Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.30 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22006030 | 0.96 | USP2 (0.32) | USP2HTTLPAR5EPHX2 | |
| SCHEMBL22266384 | 0.96 | USP2 (0.35) | USP2HTTLPAR5EPHX2SPHK1 | |
| SCHEMBL20231688 | 0.94 | USP2 (0.38) | USP2HTTLPAR5EPHX2SPHK1 | |
| SCHEMBL22296974 | 0.94 | HSD17B10 (0.32) | MEN1KMT2A | |
| SCHEMBL20323857 | 0.94 | HSD17B10 (0.32) | MEN1KMT2A | |
| SCHEMBL21472040 | 0.92 | USP2 (0.35) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL21664739 | 0.90 | USP2 (0.40) | USP2HTTLPAR5SPHK1CYP1A2 | |
| SCHEMBL20230960 | 0.90 | USP2 (0.32) | USP2HTTLPAR5 | |
| SCHEMBL22006057 | 0.88 | USP2 (0.33) | USP2HTTLPAR5SPHK1 | |
| SCHEMBL20372890 | 0.85 | EPHX2 (0.33) | HTTEPHX2MEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2020023851-A1 | BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE | YALE UNIVERSITY (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | USP2 11/4885HTT 748/4885LPAR5 3936/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | USP2 28/4885HTT 417/4885LPAR5 3609/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | USP2 11/4885HTT 748/4885LPAR5 3936/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | USP2 29/4885HTT 1200/4885LPAR5 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.